Sutro Biopharma, Inc.
STRO
$30.52
$0.973.28%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 24.69% | 20.16% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 24.69% | 20.16% | |||
| Cost of Revenue | -97.81% | -8.06% | |||
| Gross Profit | 154.90% | 17.13% | |||
| SG&A Expenses | -12.45% | -0.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.58% | -6.77% | |||
| Operating Income | 12.01% | 13.48% | |||
| Income Before Tax | 17.81% | 17.61% | |||
| Income Tax Expenses | 81.71% | -- | |||
| Earnings from Continuing Operations | 17.70% | 17.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 17.70% | 17.76% | |||
| EBIT | 12.01% | 13.48% | |||
| EBITDA | 11.54% | 13.43% | |||
| EPS Basic | 45.06% | 20.08% | |||
| Normalized Basic EPS | 39.52% | 12.78% | |||
| EPS Diluted | 45.06% | 20.08% | |||
| Normalized Diluted EPS | 39.52% | 12.78% | |||
| Average Basic Shares Outstanding | 49.79% | 2.91% | |||
| Average Diluted Shares Outstanding | 49.79% | 2.91% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||